Parcourir par auteur "Symeonidis, A."
Voici les éléments 1-6 de 6
-
99mTc sestamibi as a prognostic factor of response to first-line therapy and outcome in patients with malignant lymphoma
(2013)INTRODUCTION: Resistance to chemotherapy poses a major problem in cancer patients. Although of multifactorial origin, some of the implicated mechanisms also interfere with Tc-MIBI uptake and retention in cancer cells. The ... -
Efficacy of Interferon A-2b Monotherapy in B-Thalassemics with Chronic Hepatitis C
(2015)Background & Aims: Monotherapy with standard or pegylated interferon (PegIFN) remains the first-line treatment for HCV infection in patients with thalassemia major (beta TM), although its long-term impact is still unknown. ... -
Overexpression of phosphorylated p27(Kip1) at threonine 187 may predict outcome in aggressive B-cell lymphomas
(2011)Phosphorylation of p27<SUKip1</SU at threonine 187 (pThr187-p27<SUKip1</SU) occurs frequently in the development of human tumors, directing protein polyubiquitination and subsequent proteasomal degradation. We investigated ... -
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
(2014)Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder, with poor outcome. Bortezomib-based regimens (BBR) are highly effective in myeloma, but there is limited information about their efficacy and safety ...